TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03841981

Intervention type: PROCEDURE
Intervention: Percutaneous biopsy
Description: Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Intervention type: PROCEDURE
Intervention: Percutaneous biopsy
Description: Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic function studies
Description: Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic function studies
Description: Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic function studies
Description: Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic function studies
Description: Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic function studies
Description: Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral smear and feces specimen
Description: Microbiome studies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral smear and feces specimen
Description: Microbiome studies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral smear and feces specimen
Description: Microbiome studies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral smear and feces specimen
Description: Microbiome studies.
Study: NCT03822910

Intervention type: DIAGNOSTIC_TEST
Intervention: Sequential Associative Mismatch Paradigm
Description: used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).

Intervention type: DIAGNOSTIC_TEST
Intervention: Encoding Plasticity Paradigm
Description: Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.

Intervention type: DIAGNOSTIC_TEST
Intervention: Encoding Plasticity Paradigm
Description: Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
Study: NCT03777514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: treatment of iron deficiency anemia with IV iron.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: treatment of iron deficiency anemia with oral iron

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral vitamin C
Description: Oral vitamin C to be used as a placebo for participants receiving IV iron

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous normal saline
Description: Intravenous normal saline will be used as placebo for participants receiving oral iron
Study: NCT02176486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib placebo-matching capsules.
Study: NCT03481530

Intervention type: DEVICE
Intervention: Continuing Glucose Monitor System
Description: glucose monitoring

Intervention type: DEVICE
Intervention: Continuing Glucose Monitor System
Description: glucose monitoring
Study: NCT05066685

Intervention type: OTHER
Intervention: All participants
Description: All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
Study: NCT02351102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01492010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: 25 g whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplemented with leucine
Description: 6.25 g whey protein supplemented with free form leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplemented with essential amino acids
Description: 6.25 g whey protein supplemented with essential amino acids devoid of leucine
Study: NCT03505268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
Study: NCT04239209

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indirect - other patients
Description: Video depicting an indirect response focusing on a comparison to other patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indirect - physiology
Description: Video of an indirect response focusing on the physiology of the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Redirection
Description: Video of a redirection towards discussing the patient's values and possible future decisions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Direct communication
Description: Video of a direct response.
Study: NCT04814979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Description: Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities \<100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days.
Study: NCT02846519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 2 capsules (300 mg each) of rifampin.
Study: NCT00336102

Intervention type: OTHER
Intervention: physiologic testing
Description: Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.

Intervention type: OTHER
Intervention: physiologic testing
Description: Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.

Intervention type: PROCEDURE
Intervention: fatigue assessment and management
Description: Fatigue Symptoms Inventory (FSI) survey

Intervention type: PROCEDURE
Intervention: fatigue assessment and management
Description: Fatigue Symptoms Inventory (FSI) survey

Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control

Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
Study: NCT03494283

Intervention type: BEHAVIORAL
Intervention: Practice Behaviour
Description: Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
Study: NCT00815646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
Study: NCT03146286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated fat
Description: Palm stearin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil, Omega 3 PUFA
Study: NCT04558697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shepherd's Purse extractum oleosum vagitories
Description: Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tea tree oil vagitories
Description: Tea tree oil vagitories will be administered once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperici extractum oleosum vagitories
Description: Hyperici extractum oleosum vagitories will be administered once daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vagitories - Probiotic
Description: Vagitories - Probiotic will be administered once daily for 5 days
Study: NCT02582671

Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Co-formulated tablet

Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet

Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study: NCT01276288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: multiple oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: torasemide
Description: multiple oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torasemide
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: multiple oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: multiple oral doses
Study: NCT03377634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORPH
Description: Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
Study: NCT04028037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FTPGT treated patients
Description: The recipient bed will be prepared according to Langer\&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+SCTG treated patients
Description: According to De Sanctis \& Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
Study: NCT03582111

Intervention type: OTHER
Intervention: Study of medical records
Description: Study of medical records
Study: NCT01442025

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab
Description: Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
Study: NCT04237493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Glimepiride (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 1.5 or 3 mg \[75% of the pre-Ramadan dose\]; OD \[with Ifṭār\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Vildagliptin (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; OD \[with Ifṭār\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Insulin Glargine U100 (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 9-33 units \[75% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr \[75% of the pre-Ramadan doses\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Glimepiride (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 2 or 4 mg \[100% of the pre-Ramadan dose\]; OD \[with Ifṭār\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Vildagliptin (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; BID \[with Ifṭār and with Suḥūr\]\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Insulin Glargine U100 (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 11-44 units \[100% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr \[100% of the pre-Ramadan doses\])
Study: NCT02536586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: LY3023414 administered orally.
Study: NCT02469129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace
Description: For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace
Description: For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection.
Study: NCT01696812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrode position
Study: NCT04036825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Nutritional Supplement from Hospital Product
Description: Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard nutritional supplement is given 2 times daily as placebo for 14 days
Study: NCT03435978

Intervention type: BEHAVIORAL
Intervention: MetS+

Intervention type: OTHER
Intervention: MetS-
Description: Data processing from Patient Medical Files
Study: NCT04525703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways for Parents after Incarceration
Description: The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
Study: NCT04626830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Intervention
Description: Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
Study: NCT01274221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD489
Description: 1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day for one week of the double-blind crossover phase
Study: NCT01496664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined CABG and PCI
Description: Coronary artery bypass grafting Percutaneous coronary intervention